Breaking News Instant updates and real-time market news.

ELF

e.l.f. Beauty

$11.11

0.225 (2.07%)

, ATUS

Altice USA

$16.63

0.26 (1.59%)

19:04
11/05/18
11/05
19:04
11/05/18
19:04

Fly Intel: After Hours Movers

UP AFTER EARNINGS: e.l.f. Beauty (ELF) up 19.4%... Altice USA (ATUS) up 9.9%... Fabrinet (FN) up 8.4%... Manitowoc (MTW) up 8.0%... nLight (LASR) up 7.5%... Mylan (MYL) up 7.1%... Booking Holdings (BKNG) up 6.6%... Mosaic (MOS) up 5.5%... RingCentral (RNG) up 5.1%... Dynavax Technologies (DVAX) up 4.3%... Nutrien (NTR) up 3.3%... Carrizo Oil & Gas (CRZO) up 2.4%.... Pandora (P) up 2.3%... Syndax Pharma (SNDX) up 1.2%... Argo Group (ARGO) up 1.0%. ALSO HIGHER: AVEO Pharma (AVEO) up 2.4% after announcing its Phase-3 TIVO trial met primary endpoint. DOWN AFTER EARNINGS: frontdoor (FTDR) down 18.7%... Rayonier (RYAM) down 15.0%... Cohu (COHU) down 10.0%... IntriCon Corp (IIN) down 9.9%... Continental Reserouce Development (CDEV) down 9.8%... 2U (TWOU) down 9.6%... Nevro Corp (NVRO) down 6.3%... Neurocrine Biosciences (NBIX) down 5.9%... PTC Therapeutics (PTCT) down 5.8%... Bloom Energy (BE) down 5.7%... Marriott (MAR) down 5.1%... Avis Budget (CAR) down 4.6%... Tenet Healthcare (THC) down 4.3%... Resolute Energy (REN) down 3.5%... Oasis Petroleum (OAS) down 3.5%... Laredo Petroleum (LPI) down 3.1%... Team Inc (TISI) down 2.7%... Akcea Therapeutics (AKCA) down 2.2%... Andersons (ANDE) down 1.9%... Acadia Healthcare (ACHC) down 1.4%... Valvoline (VVV) down 1.1%... Luminex (LMNX) down 0.9%.

ELF

e.l.f. Beauty

$11.11

0.225 (2.07%)

ATUS

Altice USA

$16.63

0.26 (1.59%)

FN

Fabrinet

$45.18

-1.34 (-2.88%)

MTW

Manitowoc

$19.13

0.42 (2.24%)

LASR

nLight

$19.26

-1.23 (-6.00%)

MYL

Mylan

$31.36

-0.31 (-0.98%)

BKNG

Booking Holdings

$1,881.90

8.61 (0.46%)

MOS

Mosaic

$32.24

0.34 (1.07%)

RNG

RingCentral

$74.98

-1.915 (-2.49%)

DVAX

Dynavax

$11.12

-0.27 (-2.37%)

NTR

Nutrien

$54.23

-0.97 (-1.76%)

CRZO

Carrizo Oil & Gas

$18.36

0.64 (3.61%)

P

Bought by SIRI

$8.66

-0.01 (-0.12%)

SNDX

Syndax

$4.84

-0.285 (-5.56%)

ARGO

Argo Group

$61.67

0.13 (0.21%)

AVEO

Aveo Pharmaceuticals

$2.53

-0.25 (-8.99%)

FTDR

Frontdoor

$35.17

0.17 (0.49%)

RYAM

Rayonier Advanced Materials

$13.36

0.36 (2.77%)

COHU

Cohu

$21.50

-0.5 (-2.27%)

IIN

IntriCon

$44.35

2.205 (5.23%)

CDEV

Centennial Resource Development

$20.21

0.67 (3.43%)

TWOU

2U

$63.27

-0.56 (-0.88%)

NVRO

Nevro

$45.65

-2 (-4.20%)

NBIX

Neurocrine

$110.55

-5.28 (-4.56%)

PTCT

PTC Therapeutics

$38.02

-1.59 (-4.01%)

BE

Bloom Energy

$23.08

0.22 (0.96%)

MAR

Marriott

$120.74

-0.14 (-0.12%)

CAR

Avis Budget

$31.10

0.965 (3.20%)

THC

Tenet

$27.20

0.05 (0.18%)

REN

Resolute Energy

$30.97

0.66 (2.18%)

OAS

Oasis Petroleum

$10.23

0.37 (3.75%)

LPI

Laredo Petroleum

$5.44

0.15 (2.84%)

TISI

Team

$19.53

-0.37 (-1.86%)

AKCA

Akcea Therapeutics

$27.03

1.73 (6.84%)

ANDE

Andersons

$37.00

0.37 (1.01%)

ACHC

Acadia

$40.49

-4.27 (-9.54%)

VVV

Valvoline

$20.78

0.395 (1.94%)

LMNX

Luminex

$29.61

-0.32 (-1.07%)

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

  • 28

    Nov

  • 01

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

ELF e.l.f. Beauty
$11.11

0.225 (2.07%)

09/13/18
JPMS
09/13/18
NO CHANGE
Target $11
JPMS
Underweight
e.l.f. Beauty recent 20% rally a shorting opportunity, says JPMorgan
JPMorgan analyst Andrea Teixeira recommends using the recent 20% rally in shares of e.l.f. Beauty as an opportunity to short the stock. While the analyst agrees with Marathon Partners that e.l.f. has room to cut spending, she believes "significant levels" of reinvestment will still be required even if compensation is reduced. On Marathon's second proposal of putting the company up for sale, Teixeira is less optimistic on the potential to find a strategic buyer given the "significant sales deceleration" e.l.f is facing. The analyst is also less optimistic on e.l.f.'s takeout valuation potential. She notes that publicly available transaction comps on recent mass beauty companies would imply a takeout valuation range of $278M, or a 66% discount to current levels, to $695M, or a 9% premium. Teixeira remains skeptical on e.l.f. Beauty's growth prospects and keeps an Underweight rating on the shares with an $11 price target.
09/12/18
WBLR
09/12/18
NO CHANGE
WBLR
e.l.f. Beauty could generate corporate takeover interest, says William Blair
Following the Wall Street Journal's report that Marathon Partners plans to advocate that the company start a process to sell itself, William Blair analyst Jon Andersen said he believes e.l.f. Beauty could generate interest among potential corporate buyers. e.l.f. appeals to an attractive set of core user groups and maintains a strong value proposition based on high quality color cosmetics made available at very attractive price points, Andersen tells investors in a research note. He sees "option value in a potential sale" and keeps an Outperform rating on e.l.f. Beauty.
08/13/18
RHCO
08/13/18
NO CHANGE
Target $14
RHCO
Buy
e.l.f. Beauty price target lowered to $14 from $18 at SunTrust
SunTrust analyst William Chappell lowered his price target on e.l.f. Beauty to $14 after its latest cut in FY18 guidance last week, saying the company has had "years of flat to declining sales trends" while its management ignored the Nielsen market data. Chappell is also keeping his Buy rating while acknowledging that he is "one of the last" sell-side analysts to stay at Buy. Chappell says that although the damage is done, e.l.f. Beauty is planning a "major step up in advertising and promotional spending", and that it is "too early" to suggest that the initiative is too late. The analyst also believes that the recent negative trends is still not indicative of lost listing and shelf space for the company, adding that the stock price selloff is more of a reflection on confidence rather then results.
08/10/18
DADA
08/10/18
NO CHANGE
Target $72
DADA
Buy
Inter Parfums price target raised to $72 from $62 at DA Davidson
DA Davidson analyst Linda Bolton Weiser raised her price target on Inter Parfums (IPAR) to $72 and kept her Buy rating after its Q2 surprise, noting that the 4% decline in the stock price yesterday in concert with the negative earnings news from e.l.f. Beauty (ELF) is an "excellent buying opportunity". Weiser notes that Inter Parfums has strong business momentum, and the stock is set up for more potential upside surprises given the management's "conservative" 2018 guidance.
ATUS Altice USA
$16.63

0.26 (1.59%)

10/23/18
10/23/18
NO CHANGE

Guggenheim assumes select Cable/Satellite names with positive outlook
Guggenheim analyst Mike McCormack assumed coverage of select Cable & Satellite Services companies with a positive outlook, saying that while each company is facing "video headwinds", they also offer shared catalysts of "the demand for broadband connectivity, increasingly faster speeds, and new wireless products". The analyst assumes Altice USA (ATUS), Charter (CHTR) and Dish (DISH) with Buy ratings and Comcast (CMCSA) with a Neutral rating, adding that its "business is in transition" with core risks around domestic and international operations. McCormack puts a $23 price target on Altice USA, $400 price target on Charter, $38 price target on Comcast, and a $50 price target on Dish, adding that the "importance of the bundle is diminishing" and the focus shifts to the scope of connectivity coverage. The analyst also expects the "younger demographic" to continue to seek out "lower cost, apps-based alternatives, with an eye towards free/cheap, but high-demand content".
10/23/18
GUGG
10/23/18
INITIATION
Target $23
GUGG
Buy
Altice USA assumed with a Buy at Guggenheim
Guggenheim analyst Mike McCormack assumed coverage of Altice USA with a Buy rating while lowering his firm's price target for the shares to $23 from $24. The rating is unchanged from the prior analyst's coverage.
08/09/18
RBCM
08/09/18
NO CHANGE
Target $25
RBCM
Outperform
Altice USA price target lowered to $25 from $31 at RBC Capital
RBC Capital analyst Jonathan Atkin lowered his price target on Altice USA to $25 after its lower than expected Q2 EBITDA, citing pressure coming from one-time items. The analyst keeps his Outperform rating, noting that revenue and adjusted EBITDA should accelerate in the second half of the year with pricing increases and political advertising revenue.
07/10/18
FBCO
07/10/18
INITIATION
Target $21
FBCO
Outperform
Altice USA initiated with an Outperform at Credit Suisse
Credit Suisse analyst Doug Mitchelson initiated Altice USA with an Outperform and $21 price target citing an expected 2H 2018 revenue acceleration with a potential return of stock repurchases within the year.
FN Fabrinet
$45.18

-1.34 (-2.88%)

10/22/18
STFL
10/22/18
INITIATION
Target $53
STFL
Buy
Fabrinet resumed with a Buy at Stifel
Stifel analyst John Marchetti resumed Fabrinet with a Buy rating and a price target of $53, citing the company's position as a "niche solution provider" with a growing total addressable market. The analyst further notes that Fabrinet's customer "diversification strategy" toward lasers, sensors, and other complex opto-electronics positions it for "solid growth" and margins rising back above 12%. Marchetti anticipates the company to grow its EPS by double digits in FY19 and FY20 thanks to its "tight cost controls and a continued share buyback program".
09/04/18
RILY
09/04/18
DOWNGRADE
Target $54
RILY
Neutral
II-VI downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Dave Kang downgraded II-VI to Neutral citing valuation and macro uncertainty. The analyst keeps a $54 price target for the shares. Kang this morning also downgraded Fabrinet (FN) citing a similar rationale.
09/04/18
RILY
09/04/18
DOWNGRADE
Target $52
RILY
Neutral
Fabrinet downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Dave Kang downgraded Fabrinet to Neutral citing valuation and macro uncertainty. The analyst keeps a $52 price target for the shares.
08/21/18
08/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Equal Weight from Overweight at Consumer Edge with the firm saying SEC issues and news headlines will leave shares "boxed-in" near-term. 2. HP Enterprise (HPE) downgraded to Market Perform from Outperform at Bernstein with analyst A.M. Sacconaghi, Jr. saying despite a robust IT spending environment, he does not see upside to near-term expectations, given tough comparisons, continuing share losses in servers, a headwind from currency, an expected higher tax rate, and lower other income. 3. Fabrinet (FN) downgraded to Buy from Strong Buy at Needham with analyst Alex Henderson citing valuation. 4. Hudson Pacific (HPP) downgraded to Neutral from Outperform at Baird with analyst David Rodgers saying he sees downside risk in consensus estimates during both 2019 and 2020 and as a result, he believes it will be difficult to outperform. 5. Brixmor (BRX) downgraded to Neutral from Buy at Mizuho with analyst Haendel St. Juste citing share strength since mid-February and the near-term dilutive impact of the company's strategy shift to ramp up 2018 dispositions to capitalize on better than expected asset pricing. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MTW Manitowoc
$19.13

0.42 (2.24%)

09/20/18
BARD
09/20/18
UPGRADE
Target $32
BARD
Outperform
Manitowoc upgraded to Outperform at Baird
As reported previously, Baird analyst Mig Dobre upgraded Manitowoc to Outperform from Neutral. The analyst sees good execution through 2018 with continued margin expansion, order growth, and the ability to manage supply chain restraints. Dobre raised his price target to $32 from $27 on Manitowoc shares.
09/20/18
BARD
09/20/18
UPGRADE
BARD
Outperform
Manitowoc upgraded to Outperform from Neutral at Baird
07/17/18
07/17/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ANALYSTS SPLIT ON NETFLIX AFTER EARNINGS: Despite continuing to like Netflix's story, Deutsche Bank analyst Bryan Kraft downgraded Netflix (NFLX) to Hold from Buy as he believes that the "slowdown in growth" requires a "reevaluation of value." Meanwhile, both BMO Capital and Stifel upgraded the stock to Buy-equivalent ratings as they see the post-earnings weakness in the shares as a buying opportunity. BMO analyst Daniel Salmon raised Netflix to Outperform, with a $400 price target, saying the decline in the stock price following quarterly results offers investors an attractive level to build positions. Stifel also upgraded Netflix to Buy from Hold, with a $406 price target. Analyst Scott Devitt cited the potential for near-term subscription add expectations to reset, a strong second half of the year content slate, and a domestic and international runway, which supports a doubling of the company's subscriber base in the next five to ten years. STEPHENS SEES OPPORTUNITY IN TRIBUNE SELLOFF: Stephens analyst Kyle Evans upgraded Tribune Media (TRCO) to Overweight from Equal Weight while lowering his price target for the shares to $41 from $45. Statements from the FCC and reports by Reuters on Monday created investor concern around whether Sinclair Broadcast (SBGI) will be able to close its proposed acquisition of Tribune, Evans told investors. The analyst said he believes the FCC will allow Sinclair to remedy its concerns about proposed divestiture buyers and that Sinclair will comply with all requirements in an effort to close the deal. He believes a combination of the two companies "remains the best possible outcome for both parties." GOLDMAN SACHS DOWNGRADES MACHINERY MAKERS: Goldman Sachs analyst Jerry Revich downgraded Manitowoc (MTW) to Sell from Neutral and lowered his price target to $22 from $30 as part of his broader note on the machinery cycle. The analyst also downgraded Generac (GNRC) to Sell from Neutral with an unchanged price target of $45 and removed Caterpillar (CAT) and Deere (DE) from the firm's Conviction Buy lists. GOLDMAN ALSO DOWNGRADES GOODYEAR: Goldman Sachs analyst David Tamberrino downgraded Goodyear Tire & Rubber (GT) to Sell from Neutral and lowered his price target for the shares to $18 from $25. The analyst said he sees the "tough backdrop" for the company continuing amid raw material price increases. Further, Goodyear's pricing power "remains elusive," Tamberrino told investors in a research note.
07/16/18
GSCO
07/16/18
DOWNGRADE
Target $22
GSCO
Sell
Manitowoc downgraded to Sell at Goldman Sach on weaker fundamentals
As reported earlier, Goldman Sachs analyst Jerry Revich downgraded Manitowoc (MTW) to Sell from Neutral and lowered his price target to $22 from $30 as part of his broader note on the machinery cycle. The analyst also downgraded Generac (GNRC) to Sell from Neutral with an unchanged price target of $45 and removed Caterpillar (CAT) and Deere (DE) from Conviction Buy lists. The analyst says the update on the latter two reflects more "mixed macro points", including "weaker crop prices, risk of further input cost inflation, slowing bearing orders, and a risk of further trade war escalation". Revich notes that the risk-reward on Caterpillar and Deere remains attractive, but he is more wary of rising cyclical risks. The analyst's downgrade of Manitowoc is attributed to expectations of a peak in crane organic growth in the current quarter, followed by tougher comps in Europe and the decline in U.S. rig count along with an overall "structural decline in crane content in US drilling sites and rising competitive intensity". Revich says his downgrade of Generac is driven by expectations of slower organic sales growth amid "a normalization in portable generator demand against storm period comps, a declining US rig count, tough comps on shipments into the US rental industry, and flat private non-residential construction outlook."
LASR nLight
$19.26

-1.23 (-6.00%)

10/24/18
NRCS
10/24/18
NO CHANGE
NRCS
Neutral
Northcoast finds modest rebound in Industrial Laser sentiment in September
Northcoast analyst Tom Hayes reported that his September survey of the Industrial Laser industry showed a modest rebound in sentiment following a weak outlook in August. He has seen more mixed market commentary from China as well as Coherent (COHR) indicating that its previous revenue and margin guidance would fall short of expectations following his downgrades of the laser names he covers, noted Hayes. He maintains Neutral ratings on Coherent, IPG Photonics (IPGP) and nLight (LASR).
10/23/18
NEED
10/23/18
NO CHANGE
Target $29
NEED
Buy
nLight price target lowered to $29 from $37 at Needham
Needham analyst James Ricchiuti lowered his price target on nLight to $29 following the recent pre-announcements from the industry's "major laser suppliers into the industrial and microelectronics markets". The analyst notes that while the company is better positioned than many of its peers because of its "new fiber laser products", he is also lowering his FY19 EPS view to 54c from 59c to reflect the "industry downdraft". Longer term, Ricchiuti keeps his Buy rating on nLight and believes that "shares can rebound in the next few quarters as the expected momentum from its new products begins to highlight the company's differentiation".
10/08/18
10/08/18
DOWNGRADE

Neutral
Northcoast downgrades IPG Photonics, peers to Neutral as outlook lacks clarity
As previously reported, Northcoast analyst Tom Hayes downgraded IPG Photonics (IPGP), Coherent (COHR), and nLIGHT (LASR) to Neutral from Buy as he sees considerable headwinds remaining in place, which will likely constrain unit volume growth over the next few quarters and into 2019. While the analyst continues to expect that industrial lasers, especially fiber lasers, will become an important tool in global manufacturing, the near-term challenges and lack of visibility are moving him to the sidelines as he expects the headwinds to extend into FY19 as trade and tariff issues weigh on demand. Hayes also notes that China is a significant market for laser demand, but its outsized component of total revenue adds some risk to operations. Based on the most recently published reports, trailing 12-month revenue in China represented 43% of IPG revenue, 9% of Coherent revenue, and 39% of nLIGHT's revenue, he adds.
10/08/18
NRCS
10/08/18
DOWNGRADE
NRCS
Neutral
nLight downgraded to Neutral from Buy at Northcoast
MYL Mylan
$31.36

-0.31 (-0.98%)

11/01/18
WELS
11/01/18
NO CHANGE
WELS
Market Perform
Fear of missing out helping to push Teva, Mylan higher, says Wells Fargo
Wells Fargo analyst David Maris believes Teva (TEVA) shares are bouncing back to fair value from recent declines after the company reported Q3 earnings that beat his above consensus estimate and hosted a "surprisingly bullish" quarterly call. He also sees a spillover effect occurring with Mylan (MYL) as the generic sector's advance reinforces buyers' belief that the stocks are undervalued and investors' "fear of missing out" drives increased interest. While Maris acknowledges Ajovy, Austedo, cost cuts and tax management are doing well, he believes much of Teva's business continues to show significant challenges and keeps a Market Perform rating on the shares.
10/18/18
WELS
10/18/18
NO CHANGE
WELS
Sandoz results 'potential warning signal' for generics, says Wells Fargo
Wells Fargo analyst David Maris views this morning's results from Novartis' (NVS) generic unit Sandoz as "another negative datapoint" for generic stocks, notably Teva (TEVA), Mylan (MYL) and Amneal Pharmaceuticals (AMNX). Novartis reported Sandoz net sales of $2.4B, down 4% on constant currency, and noted that sales were pressured by 8% pricing erosion in the quarter, Maris tells investors in a research note. Novartis also highlighted that U.S sales for Sandoz declined 17% due to "industry wide pricing pressure," Maris points out. The analyst views the quarter as a "potential warning signal" for the Q3 earnings season for companies with large U.S. commodity generic exposure. He maintains his caution on "generic industry margin risks."
10/12/18
WELS
10/12/18
NO CHANGE
WELS
Market Perform
Merck returning Lantus biosimilar rights negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris sees a negative read-through for Mylan regarding yesterday's news of Merck Sharp & Dohme Research returning the rights to biosimilar Lantus to Samsung Bioepis. While some view this as a positive, as there will likely be one fewer competitor in the market if Mylan-Biocon make it to the U.S. market, that is a "simplistic and optimistic" take, Maris tells investors in a research note. The more important factor to consider is the "why" Merck dropped out, rather than the number of competitors, the analyst writes. He believes Merck returned the rights to Samsung Bioepis due to the deteriorating pricing environment and pricing outlook for insulin and Lantus biosimilars. Lilly's and Sanofi's manufacturing capacity, along with aggressive discounting, has created a "severe pricing environment," Maris contends. He believes that if Samsung Bioepis and Merck can't make the economics work, than one should be skeptical of Mylan and Biocon having substantial success. Maris has a Market Perform rating on Mylan shares.
10/09/18
10/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Exelon (EXC) downgraded to Neutral from Overweight at JPMorgan and to Neutral from Buy at Citi. 2. CommScope (COMM) downgraded to Neutral from Buy at Goldman Sachs with analyst Mark Delaney saying he views the company's fundamental environment as "mixed" and views the stock's valuation as fair at current levels. 3. Mylan (MYL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger saying recent generics trends leave him seeing downside risk to consensus forecasts and Mylan's 2018 guidance. 4. Blackbaud (BLKB) downgraded to Market Perform from Outperform at Raymond James and JMP Securities as well as to Hold from Buy at Benchmark. 5. Kroger (KR) downgraded to Sell from Hold at Deutsche Bank while Smart & Final Stores (SFS) was downgraded to Hold from Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BKNG Booking Holdings
$1,881.90

8.61 (0.46%)

10/23/18
COWN
10/23/18
NO CHANGE
Target $2200
COWN
Outperform
Booking Holdings price target lowered to $2,200 from $2,375 at Cowen
Cowen analyst Kevin Kopelman lowered his price target on Booking Holdings to $2,200 from $2,375 to reflect greater conservatism on recent trends. The analyst lowered his estimates on nights growth, but remains bullish on the shares. Kopelman reiterated his Outperform rating on Booking Holdings shares.
10/16/18
10/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Abbott (ABT), Boston Scientific (BSX), Stryker (SYK), and Medtronic (MDT) were initiated with an Overweight at Barclays, while Baxter (BAX), Edwards Lifesciences (EW), and Zimmer Biomet (ZBH) were initiated with an Underweight. 2. Expedia (EXPE) was initiated with an Outperform at Evercore ISI, while TripAdvisor (TRIP) was initiated with an In Line, and Booking Holdings (BKNG) was initiated with an In Line. 3. Facebook (FB) was initiated with a Buy at Loop Capital and Rosenblatt. 4. Snap (SNAP) initiated with a Hold at Loop Capital. 5. VF Corp. (VFC) initiated with a Neutral at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/15/18
EVER
10/15/18
INITIATION
EVER
In Line
Booking Holdings initiated with an In Line at Evercore ISI
Evercore ISI analyst Anthony DiClemente initiated coverage of the online travel sector with a mixed outlook, starting Booking Holdings (BKNG) with an In Line rating. While the offline to online shift may have slowed, the travel market itself remains fragmented, leaving open the opportunity for share gains, said DiClemente, who calls Expedia (EXPE) his top pick in the space.
09/27/18
LEHM
09/27/18
NO CHANGE
Target $2270
LEHM
Overweight
Booking Holdings price target raised to $2,270 from $2,170 at Barclays
Barclays analyst Deepak Mathivanan raised his price target for Booking Holdings (BKNG) to $2,270 saying his analysis suggests the company has room for market share gains. At current valuations, the investment community is underestimating the "competitive moats and scale benefits" for the online travel agencies, Mathivanan tells investors in a research note. The analyst remains bullish on both Booking and Expedia (EXPE). The travel market remains healthy, Mathivanan says, who notes his outlook for global accommodations calls for stable growth in the range of mid-single digits market growth over the next few years.
MOS Mosaic
$32.24

0.34 (1.07%)

10/10/18
SBSH
10/10/18
UPGRADE
Target $40
SBSH
Buy
Citi upgrades Mosaic to Buy amid 'more favorable' phosphate demand
Citi analyst P.J. Juvekar upgraded Mosaic to Buy from Neutral and raised his price target for the shares to $40 from $36. The analyst believes phosphate supply and demand is "looking more favorable" and that fertilizer prices were strong in Q3. Prices don't need to rise much to justify a Buy rating on Moasic, Juvekar tells investors in a research note. Further, he believes phosphate prices could benefit from potential environmental restrictions in China.
10/10/18
SBSH
10/10/18
UPGRADE
SBSH
Buy
Mosaic upgraded to Buy from Neutral at Citi
10/02/18
RBCM
10/02/18
NO CHANGE
Target $40
RBCM
Outperform
Mosaic price target raised to $40 from $36 at RBC Capital
RBC Capital analyst Andrew Wong raised his price target on Mosaic to $40 and kept his Outperform rating, saying the company stands to benefit from a tightening phosphates balance because of a "lack of new capacity". The analyst also cites a "balanced potash market supported by strong shipments" as well as "constructive" agriculture fundamentals in Brazil, anticipating the stock to re-rate higher and close its valuation gap with its peer group. Wong contends that Mosaic represents an "ideal investment" in the agricultural commodity upside scenario.
09/04/18
LEHM
09/04/18
INITIATION
Target $34
LEHM
Equal Weight
Mosaic initiated with an Equal Weight at Barclays
Barclays analyst Duffy Fischer started Mosaic with an Equal Weight rating and $34 price target. The recent rally in fertilizer stocks assumes constructive market conditions will extend beyond the second half of 2018, which is less than certain, Fischer tells investors in a research note. The analyst worries that delayed new capacity is still coming and will stall the price recovery.
RNG RingCentral
$74.98

-1.915 (-2.49%)

10/29/18
JPMS
10/29/18
NO CHANGE
JPMS
JPMorgan lists potential Software takeover targets after Red Hat deal
The volume of acquisitions in Software appears to be picking up with over 70 transactions announced year-to-date including last night's Red Hat (RHT) takeover by IBM (IBM), JPMorgan analyst Sterling Auty tells investors in a research note. The analyst puts the deals announced this year into three buckets: strategic, where the acquirer looks to gain a strong foothold in a new segment, vertical acquiring companies, and valuation, with acquirers going after assets with discounted valuations. Auty sees number of companies fitting those same characteristics across his coverage universe. In the strategic category, the analyst sees Okta (OKTA), Palo Alto Networks (PANW), ServiceNow (NOW), RingCentral (RNG), Aspen Technology (AZPN) and DocuSign (DOCU) as potential acquisition targets. In the vertical industry exposure category, Auty lists Guidewire (GWRE), Veeva (VEEV), Medidata (MDSO), Ellie Mae (ELLI) and Q2 Holdings (QTWO) as potential targets. And in the attractive valuation bucket, the analyst sees FireEye (FEYE), Carbon Black (CBLK), Secureworks (SCWX), Akamai (AKAM) and LogMeln (LOGM) as potential candidates to get acquired.
10/12/18
RHCO
10/12/18
NO CHANGE
Target $100
RHCO
Buy
RingCentral acquisition of Dimelo expands its TAM, says SunTrust
SunTrust analyst Terry Tillman kept his Buy rating and $100 price target on RingCentral after its announced agreement to acquire Dimelo. The analyst notes that the acquisition presents an opportunity for the company to expand its total addressable market based on its position as a leading cloud-based digital customer engagement platform. Tillman adds that although the revenue contribution from Dimelo is immaterial, it has a notable list of customers that includes "leading organizations like Allianz, AXA, BNP Paribas, ENGIE, Orange and Telenor".
10/11/18
JEFF
10/11/18
NO CHANGE
Target $105
JEFF
Buy
Dimelo 'a valuable strategic asset' for RingCentral, says Jefferies
Jefferies analyst John DiFucci notes that RingCentral announced it plans to acquire Dimelo, a cloud-based digital customer engagement platform based in Europe. While not financially significant, the analyst sees Dimelo as a valuable strategic asset for many reasons, including that it expands RingCentral's capabilities beyond traditional UCaaS into broader digital engagement. The analyst reiterates a Buy rating and $105 price target on RingCentral's shares.
10/08/18
DBAB
10/08/18
INITIATION
DBAB
Buy
RingCentral initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Michael Turrin initiated RingCentral with a Buy rating and $105 price target.
DVAX Dynavax
$11.12

-0.27 (-2.37%)

10/22/18
JPMS
10/22/18
NO CHANGE
Target $27
JPMS
Overweight
JPMorgan expects 35%-50% rally in Dynavax after 'clear win' data
JPMorgan analyst Anupam Rama views Dynavax Technologies' update to the SD-101 plus pembrolizumab combination program as a "clear win." The analyst's focus is on the treatment naive melanoma data set, given that the presentation has the most patients at the go-forward 2mg dose level. These data hit the analyst's "upside / homerun scenario" with a 70% overall response rate. Rama sees Dynavax shares trading up in the 35%-50% range following this weekend's update. He keeps an Overweight rating on the name with a $27 price target. The stock in premarket trading is up 21%, or $2.26, to $13.15.
10/22/18
RBCM
10/22/18
NO CHANGE
Target $26
RBCM
Outperform
Dynavax price target raised to $26 from $23 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Dynavax to $26 and kept his Outperform rating after its PD-1 melanoma presentations at the European Society for Medcal Oncology Congress this weekend. The analyst notes that the findings revealed no new safety signals and continued abscopal responses across both PD-L1 positive and negative patients, which he views as the "best-case scenario for this data cut".
10/22/18
CANT
10/22/18
NO CHANGE
Target $32
CANT
Overweight
Dynavax price target raised to $32 from $30 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Dynavax Technologies (DVAX) to $32 following presentations at the European Society for Medical Oncology Congress. The data present the case for why Merck (MRK) could be a potential partner, Piros tells investors in a research note. He keeps an Overweight rating on Dynavax.
08/07/18
CANT
08/07/18
NO CHANGE
Target $30
CANT
Overweight
Dynavax price target raised to $30 from $27 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Dynavax Technologies to $30 and reiterates an Overweight rating on the shares following the company's Q2 results. The analyst believes there are a "number of opportunities in the near future for Dynavax that could lead to upside for the company," including future Heplisav-B vaccine sales and a Phase 3 trial initiation for SD-101 in advanced melanoma.
NTR Nutrien
$54.23

-0.97 (-1.76%)

10/18/18
CLVD
10/18/18
UPGRADE
CLVD
Buy
Nutrien upgraded to Buy from Neutral at Cleveland Research
09/20/18
09/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Seaspan (SSW) downgraded to Hold from Buy at Deutsche Bank with analyst Amit Mehrotra citing the recent strong performance of the shares and increased risk from the trade war between China and the U.S. 2. Bruker (BRKR) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Steve Beuchaw citing three company-specific leading indicators that he says point to a slower revenue outlook. 3. Stitch Fix (SFIX) downgraded to Neutral from Overweight at Piper Jaffray with analyst Erinn Murphy citing valuation. 4. Nutrien (NTR) downgraded to Outperform from Focus List at Scotiabank. 5. JD.com (JD) downgraded to Underperform from Outperform at CLSA with the firm lowering its price target to $29 and saying the second half will remain challenging. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/18
SCOT
09/20/18
DOWNGRADE
SCOT
Outperform
Nutrien downgraded to Outperform from Focus List at Scotiabank
09/04/18
LEHM
09/04/18
INITIATION
Target $65
LEHM
Overweight
Nutrien initiated with an Overweight at Barclays
Barclays analyst Duffy Fischer started Nutrien with an Overweight rating and $65 price target. The recent rally in fertilizer stocks assumes constructive market conditions will extend beyond the second half of 2018, which is less than certain, Fischer tells investors in a research note. The analyst worries that delayed new capacity is still coming and will stall the price recovery. However, he believes Nutrien has "significant" deal synergies to drive earnings improvement "in spite of the tough macros."
CRZO Carrizo Oil & Gas
$18.36

0.64 (3.61%)

10/29/18
IFSG
10/29/18
INITIATION
Target $22
IFSG
Outperform
Carrizo Oil & Gas initiated with an Outperform at IFS Securities
IFS Securities analyst Eli Kantor started Carrizo Oil & Gas with an Outperform rating and $22 price target. The company trades at a relative multiple discount to peers due to its below average inventory level, Kantor tells investors in a research note. The analyst, however, believes Carrizo's free cash flow and borrowing base increases should enable it to narrow the inventory gap "without further dilution."
10/29/18
IFSG
10/29/18
INITIATION
IFSG
Outperform
Carrizo Oil & Gas initiated with an Outperform at IFS Securities
10/15/18
JEFF
10/15/18
UPGRADE
Target $28
JEFF
Buy
Carrizo Oil & Gas upgraded to Buy from Hold at Jefferies
Jefferies analyst Mark Lear upgraded Carrizo Oil & Gas to Buy and raised his price target for the shares to $28 from $27. The analyst cites valuation for the upgrade as he sees an attractive entry point following the recent pullback in the shares. He believes the stock's underperformance is nearing an end.
10/02/18
OPCO
10/02/18
INITIATION
OPCO
Perform
Carrizo Oil & Gas initiated with a Perform at Oppenheimer
Oppenheimer analyst Tim Rezvan initiated Carrizo Oil & Gas with an Perform rating.
P Bought by SIRI
$8.66

-0.01 (-0.12%)

10/24/18
GSCO
10/24/18
DOWNGRADE
Target $10
GSCO
Neutral
Pandora downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Heath Terry downgraded Pandora (P) to Neutral from Buy and lowered his price target to $10 from $12 after it announced the completion of its "go-shop" period as part of the acquisition process by SiriusXM (SIRI). The analyst notes that the company now enters a "no-shop" period which "limits its ability to solicit alternative proposals", adding that the deal's fixed share exchange ratio implies a "per share price of Pandora common stock of $8.14". Terry adds that his new price target also reflects the "compression in comp group multiples".
10/01/18
BMOC
10/01/18
DOWNGRADE
Target $10
BMOC
Market Perform
Pandora downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Daniel Salmon downgraded Pandora (P) to Market Perform from Outperform and lowered his price target to $10 from $13 after last week's announcement of a takeover by SiriusXM (SIRI). Given the all-stock deal, the analyst notes that Pandora performance will be tied to that of SiriusXM in the very near term, while also assigning about a 15% probability of a competitive bid emerging during the go-shop period, which lasts until October 24th. In his bear case, to which Salmon assigns about a 5% probability, the deal for Pandora falls through because of regulatory hurdles or shareholder objection.
09/27/18
MKMP
09/27/18
NO CHANGE
Target $9.15
MKMP
Neutral
Pandora price target raised to $9.15 at MKM Partners on Sirius XM deal
MKM Partners analyst Rob Sanderson raised his price target on Pandora (P) to $9.15 from $8 after its announced agreement to be acquired by Sirius XM (SIRI), saying the deal makes strategic sense as it creates a "stronger force within the music streaming services market". The analyst notes that while Pandora has a go-shop period, he doubts that a competitive bid will emerge. Sanderson further states that while the partnership will allow Sirius to "differentiate streaming services with its strong OEM presence", the near-term should see "minimal applicability" until next-generation devices penetrate its in-car fleet. The analyst also maintains his Neutral rating on Pandora.
09/27/18
RBCM
09/27/18
DOWNGRADE
Target $10
RBCM
Sector Perform
Pandora downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Mark Mahaney downgraded Pandora (P) to Sector Perform from Outperform with a price target of $10 after its announced acquisition by Sirius XM (SIRI) expected to close in Q1 of next year. The analyst notes that the deal is a "logical strategic step between the two companies" and has been approved by both boards, adding that he sees it as "likely to close".
SNDX Syndax
$4.84

-0.285 (-5.56%)

10/29/18
OPCO
10/29/18
NO CHANGE
Target $13
OPCO
Outperform
Syndax price target lowered to $13 from $29 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Syndax to $13 from $29 after the company reported that the E2112 Phase 3 registration trial of entinostat plus exemestane in HR+/HER2- breast cancer did not meet statistical significance for PFS, nor for the third OS recently completed. The analyst reiterates an Outperform rating on the shares.
10/29/18
10/29/18
DOWNGRADE
Target $6

Equal Weight
Morgan Stanley downgrades Syndax to Equal Weight after breast cancer study miss
As previously reported, Morgan Stanley analyst David Lebowitz downgraded Syndax to Equal Weight from Overweight after the pivotal Phase 3 study that evaluated entinostat + exemestane for the treatment of HR+, HER2- breast cancer missed on its first primary endpoint of progression free survival, or PFS. Though the company will pursue a registrational strategy for the drug in combination with Keytruda for the treatment of high baseline monocyte non-small cell lung cancer, he views that strategy as high risk, Lebowitz tells investors. He no longer expects entinostat to be launched in 2020, with the more likely launch in 2021 or later, the analyst added. He reduced his price target on Syndax shares to $6 from $24 after "dialing back" his expectations for entinostat.
10/29/18
MSCO
10/29/18
DOWNGRADE
MSCO
Equal Weight
Syndax downgraded to Equal Weight from Overweight at Morgan Stanley
10/26/18
HCWC
10/26/18
NO CHANGE
Target $23
HCWC
Buy
Syndax price target lowered to $23 from $30 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for Syndax Pharmaceuticals to $23 after the company announced that the Phase 3 E2112 trial did not achieve statistical significance for the first primary endpoint of progression-free survival. The analyst moved his launch timing estimates back 12 months as he believes the overall survival opportunity is still likely. He keeps a Buy rating on Syndax.
ARGO Argo Group
$61.67

0.13 (0.21%)

10/02/18
BOSC
10/02/18
INITIATION
Target $72
BOSC
Outperform
Argo Group initiated with an Outperform at Boenning & Scattergood
Boenning & Scattergood analyst Robert Farnam initiated Argo Group Argo Group with an Outperform and $72 price target. Farnam said Argo has a good track record of growth/profitability and continues to enhance its operations via investments in technology and people. He expects underwriting performance to benefit from these investments and for a near-term improvement in net investment income due to higher interest rates.
08/07/18
KBWI
08/07/18
NO CHANGE
Target $69
KBWI
Outperform
Argo Group price target raised to $69 from $65 at Keefe Bruyette
Keefe Bruyette analyst Christopher Campbell raised his price target for Argo Group to $69 citing the company's Q2 beat, lower catastrophes, and higher fee income. The analyst reiterates an Outperform rating on the shares.
AVEO Aveo Pharmaceuticals
$2.53

-0.25 (-8.99%)

10/22/18
PIPR
10/22/18
NO CHANGE
Target $5
PIPR
Overweight
TiNivo data competitively position Aveo Pharmaceuticals, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes the data for tivozanib combined with Opdivo to treat metastatic renal cell carcinoma presented at the ESMO meeting competitively position Aveo Pharmaceuticals as the treatment landscape for front-line RCC moves to I-O and TKI combinations. An ORR of 56% and DCR of 96% represent "promising early activity," said Tenthoff., who reiterates his Overweight rating and $5 target on Aveo shares.
10/01/18
PIPR
10/01/18
NO CHANGE
Target $5
PIPR
Overweight
Piper remains confident in Aveo reporting positive TIVO-3 data
After an Independent Steering Committee recommended the initiation of top-line analysis of Aveo Pharmaceuticals' Phase 3 TIVO-3 trial of tivozanib in third-line renal cell carcinoma, Piper Jaffray analyst Edward Tenthoff noted that the lower than expected event rate of 242 events "minimally reduces" powering of the trial to 88% from the originally planned for 90%, but he remains confident in positive top-line TIVO-3 data being reported in about 6 weeks. Tenthoff reiterates his Overweight rating and $5 price target on Aveo shares.
08/16/18
08/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Post Holdings (POST) initiated with an Overweight at Piper Jaffray. 2. Stryker (SYK) initiated with a Buy at BTIG. 3. Aveo Pharmaceuticals (AVEO) initiated with a Buy at H.C. Wainwright. 4. Uxin (UXIN) initiated with a Buy at Goldman Sachs. 5. AcelRx (ACRX) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/18
HCWC
08/16/18
INITIATION
Target $6.5
HCWC
Buy
Aveo Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated Aveo Pharmaceuticals (AVEO) with a Buy rating and $6.50 price target, citing the view that tivozanib offers potentially the "best-in-class" safety profile when compared to leading TKIs on the market, such as Pfizer's (PFE) Sutent and Bayer's (BAYRY) Nexavar. Ramakanth projects tivozanib to reach the U.S. market in 2020 and achieve risk-adjusted revenues of $651M by 2030.
FTDR Frontdoor
$35.17

0.17 (0.49%)

10/03/18
SPIN
10/03/18
DOWNGRADE
SPIN
Hold
Frontdoor downgraded to Hold from Buy at Spin-Off Research
10/03/18
10/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. XPO Logistics (XPO) initiated with a Buy at Jefferies. 2. Allegiance Bancshares (ABTX) initiated with a Strong Buy at Raymond James. 3. 21Vianet (VNET) initiated with a Buy at Jefferies. 4. Frontdoor (FTDR) initiated with a Buy at Gabelli. 5. Anixa Biosciences (ANIX) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/18
STFL
10/03/18
NO CHANGE
Target $45
STFL
Buy
ServiceMaster price target raised to $45 from $40 at Stifel
Stifel analyst Michael Hoffman raised his price target on ServiceMaster (SERV) to $45 from $40 stating that better service, which results in higher retention, should lead to better margins and free cash flow conversion in the Pest Control segment while the Franchise Services Group should remain highly profitable and reliable. He also notes that ServiceMaster owns 19.9% of Frontdoor (FTDR) after the spinoff and that ownership should add $5 per share in value at the current market valuation of the newly-public company. Hoffman maintains a Buy rating on ServiceMaster shares.
10/02/18
GABE
10/02/18
INITIATION
GABE
Buy
Frontdoor initiated with a Buy at Gabelli
RYAM Rayonier Advanced Materials
$13.36

0.36 (2.77%)

07/12/18
07/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Galmed (GLMD) initiated with an Overweight at Cantor Fitzgerald. 2. VF Corp. (VFC) initiated with a Buy at Deutsche Bank. 3. NetApp (NTAP) initiated with a Buy at Guggenheim. 4. Rayonier Advanced Materials (RYAM) initiated with a Buy at Berenberg. 5. Ebix (EBIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/18
BREN
07/12/18
INITIATION
Target $25
BREN
Buy
Rayonier Advanced Materials initiated with a Buy at Berenberg
Berenberg analyst Paretosh Misra initiated Rayonier Advanced Materials with a Buy and $25 price target given expectations for a rebound in EBITDA per tonne in the core cellulose business, overly bearish expectations on self-help initiatives and M&A synergies, and possible accelerated stock buybacks.
05/09/18
VERT
05/09/18
UPGRADE
VERT
Buy
Rayonier Advanced Materials upgraded to Buy from Hold at Vertical Research
03/27/18
BOFA
03/27/18
NO CHANGE
BOFA
Ciena, Rayonier Advanced Materials added to Endeavor list at BofA/Merrill
BofA/Merrill portfolio strategist Derek Harris removed DST Systems (DST) and Camping World (CWH) from the firm's Endeavor list, which selects approximately 15 to 25 small cap stocks the firm views as most compelling using a multi-disciplinary process. Ciena (CIEN) was added to the list, with Harris noting a continued upcycle in spending on 100-gigabit optical equipment and upside on data center interconnect growth as potential catalysts. Rayonier Advanced Materials (RYAM) was also added to the list, with the recent acquisition of Tembec cited as potentially accretive to EPS and free cash flow.
COHU Cohu
$21.50

-0.5 (-2.27%)

09/24/18
DADA
09/24/18
INITIATION
Target $30
DADA
Buy
Cohu initiated with a Buy at DA Davidson
DA Davidson analyst Thomas Diffely initiated Cohu with a price target of $30, saying the company has a "slew" of growth drivers along with its "attractive" valuation. The analyst cites Cohu's position as a "leading provider of semiconductor test handlers and an emerging player in the associated contactor and vision inspection markets", anticipating significant stock appreciation over the next few years. Diffely also believes that the company is "severely undervalued" and points to "robust" core semiconductor handler industry trends in markets that are experiencing multi-year expansions, with the stock trading at 8-times expected 2019 earnings vs. the broader group's 10-times multiple.
05/29/18
STFL
05/29/18
DOWNGRADE
Target $14
STFL
Hold
Xcerra downgraded to Hold from Buy at Stifel
Stifel analyst Patrick Ho downgraded Xcerra (XCRA) to Hold from Buy citing his belief that its acquisition by Cohu (COHU) will be completed before year end. The analyst, who raised his price target for Xcerra to $14 from $13, does not believe there will be any competitive bids and sees the deal passing U.S. and European regulatory hurdles.
05/25/18
DADA
05/25/18
NO CHANGE
Target $14
DADA
Neutral
Xcerra attractive in either scenario of Cohu deal uncertainty, says DA Davidson
DA Davidson analyst Thomas Diffely keeps his Neutral rating and $14 price target on Xcerra (XCRA), saying that its "solid" results and momentum from recent share gains make it an attractive investment regardless of the outcome of the pending Cohu (COHU) acquisition. The analyst notes that the regulatory process has been unpredictable over the past year, but he is positive on the stock based on the "combination of a somewhat modest premium to be paid by Cohu and the strong underlying business activity".
05/09/18
RILY
05/09/18
DOWNGRADE
Target $14
RILY
Neutral
Xcerra downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Craig Ellis downgraded Xcerra (XCRA) to Hold and lowered his price target for the shares to $14 from $15 to reflect the takeover by Cohu (COHU).
IIN IntriCon
$44.35

2.205 (5.23%)

09/21/18
STFL
09/21/18
NO CHANGE
Target $70
STFL
Buy
IntriCon price target raised to $70 from $65 at Stifel
Stifel analyst Jonathan Block raised his price target on IntriCon (IIN) to $70 from $65 by assigning what he called "relatively conservative sales multiples" to his forecasts for the company's Medical and Hearing businesses, but he also contends that margin expansion will play an important part to IntriCon's story in the coming years, giving the stock a path toward $100 per share. Block, who believes IntriCon's traction with Medtronic (MDT) gives it a long runway for growth, keeps a Buy rating on the shares.
09/17/18
RILY
09/17/18
NO CHANGE
Target $73
RILY
Buy
IntriCon 22% pullback brings 'unique entry point,' says B. Riley FBR
B. Riley FBR analyst Andrew D'Silva believes the 22% pullback in shares of IntriCon since September 10 provide a "unique entry point." The analyst continues to believe that market does not fully understand what improved attachment rates could mean for IntriCon's bottom line. He keeps a Buy rating on the shares with a $73 price target.
09/11/18
DOTC
09/11/18
DOWNGRADE
DOTC
Neutral
IntriCon downgraded to Neutral from Buy at Dougherty
08/22/18
RILY
08/22/18
NO CHANGE
Target $73
RILY
Buy
IntriCon price target raised to $73 from $62 at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva raised his price target for IntriCon to $73 to reflect revised share count assumptions and stronger diabetes/hearing aid growth. The analyst maintains a Buy rating on the shares following the company's $95M equity offering.
CDEV Centennial Resource Development
$20.21

0.67 (3.43%)

09/07/18
RHCO
09/07/18
UPGRADE
Target $25
RHCO
Buy
Centennial Resource Development upgraded to Buy at SunTrust on output prospects
As reported earlier, SunTrust analyst Neal Dingmann upgraded Centennial Resource Development (CDEV) to Buy from Hold and raised his price target to $25 from $20. The analyst cites the company's "operational strides" to ensure that its 2020 production goal is achieved while also noting its "pricing diversification" efforts through its latest crude agreement with Exxon Mobil (XOM) as well as its position of an "early mover" among Permian E&Ps on the gas side. Dingmann advises that investors take advantage of the current "opportune entry point" given Centennial Resource Development's "below peer valuation".
09/07/18
RHCO
09/07/18
UPGRADE
RHCO
Buy
Centennial Resource Development upgraded to Buy from Hold at SunTrust
08/29/18
LEHM
08/29/18
INITIATION
Target $24
LEHM
Overweight
Centennial Resource Development initiated with an Overweight at Barclays
Barclays analyst Jeanine Wai started Centennial Resource Development with an Overweight rating and $24 price target. The analyst initiated coverage of eight large-cap and three smid-cap Exploration & Production companies in the North America oil & gas industry with a Positive view. Increased capital discipline, technology-driven efficiency gains, "fortified" balance sheets and a supportive oil price outlook should drive improving shareholder returns and stock price performance, Wai tells investors in a research note.
08/23/18
JEFF
08/23/18
INITIATION
Target $23
JEFF
Buy
Centennial Resource Development initiated with a Buy at Jefferies
Jefferies analyst Zach Parham started Centennial Resource Development with a Buy rating and $23 price target.
TWOU 2U
$63.27

-0.56 (-0.88%)

10/24/18
10/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at JMP Securities. 2. Comcast (CMCSA) resumed with a Buy at Deutsche Bank, reinstated with a Buy at Citi, and assumed with a Neutral at Guggenheim. 3. 2U (TWOU) initiated with a Buy at Needham. 4. Corbus Pharmaceuticals (CRBP) initiated with a Buy at B. Riley FBR. 5. Entasis Therapeutics (ETTX) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/18
NEED
10/24/18
INITIATION
Target $80
NEED
Buy
2U initiated with a Buy at Needham
Needham analyst Ryan MacDonald initiated 2U with a Buy rating and a price target of $80, citing its offering of a "cloud-based software platform" designed to "bring university partners into the digital age via online graduate degree and short course programs". The analyst expects the company to capture additional market share based on the continued strong demand for online programs and the "continued scaling of the short course segment", anticipating a 30% annual revenue growth through FY20. MacDonald further contends that the graduate program segment opportunity is poised for accelerating growth, adding that the 5.5-times enterprise value to expected FY19 sales valuation multiple of 2U is attractive.
10/23/18
NEED
10/23/18
INITIATION
Target $80
NEED
Buy
2U initiated with a Buy at Needham
Needham initiated 2U with a Buy and $80 price target.
09/06/18
PIPR
09/06/18
INITIATION
Target $94
PIPR
Neutral
2U initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Peter Appert started 2U with a Neutral rating and $94 price target. The company has a "large market opportunity and robust near-term revenue momentum," but its valuation at current share levels is "rich," Appert tells investors in a research note. The analyst also sees limited visibility into the timing of a turn to positive free cash flow. He'd look for opportunities to become more aggressive on any share pullbacks.
NVRO Nevro
$45.65

-2 (-4.20%)

10/19/18
GSCO
10/19/18
DOWNGRADE
Target $44
GSCO
Sell
Nevro downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Isaac Ro downgraded Nevro (NRVO) to Sell and lowered his price target for the shares to $44 from $60. The company's cycle of negative estimate revisions is not yet over, Ro tells investors in a research note where he also upgraded DexCom (DXCM) to Neutral. The analyst thinks consensus revenue expectations for Nevro are still too high amid "ramping" competition, the company's ongoing patent litigation with Boston Scientific (BSX) and the hiring disruption in its sales force.
07/25/18
WBLR
07/25/18
NO CHANGE
WBLR
Outperform
Nevro patent ruling not as bad as it seems, says William Blair
William Blair analyst Margaret Kaczor says the summary judgement issued yesterday is not as bad as it seems for Nevro (NVRO). While the initial headline appears negative, the ruling is similar to the preliminary judgment published earlier this month, Kaczor tells investors in a research note. Though some of the claims in the patents have been invalidated, the remaining claims, which include frequency ranges of 1.5 kHz to 100 kHz, were not invalidated, the analyst adds. She points out, though, that the judge found Boston Scientific (BSX) did not infringe on the claims as its commercially available devices could not be programmed to frequencies that would infringe and that devices that could be programmed to high frequency that are being used in clinical trials are included in safe harbor provisions. This leaves the door open in the event that Boston commercially launches a device within the frequency ranges referenced above, Kaczor writes. She believes, however, that even if Boston moves to launch a high frequency device in the United States, the company would likely have to file for FDA approval following the completion of its high-frequency trial. Despite some level of uncertainty this ruling may bring, Nevro's risk/reward is favorable, Kaczor contends. She keeps an Outperform rating on the shares.
07/25/18
LEER
07/25/18
NO CHANGE
Target $90
LEER
Outperform
Nevro selloff overdone, says Leerink
Leerink analyst Danielle Antalffy is defending Nevro (NVRO) shares after a 26% selloff in response to a summary judgment ruling in which either the company's patents were ruled invalid or Boston Scientific (BSX) was ruled to not infringe. The analyst believes that even in a worst-case scenario, namely one in which Nevro's patents are invalidated, allowing other manufacturers to pursue high frequency therapy, the company would still be able to grow sales by about 5% in 2019. Antalffy reiterates an Outperform rating and $90 price target on Nevro's shares as she continues to believe the company's fundamentals remain relatively strong, particularly given where the stock is currently trading.
07/25/18
ADAM
07/25/18
NO CHANGE
Target $80
ADAM
Buy
Nevro weakness a buying opportunity, says Canaccord
Canaccord analyst Jason Mills said the weakness in Nevro (NVRO) following a summary judgment announced yesterday in its patent dispute with Boston Scientific (BSX) is a buying opportunity. The analyst said the move yesterday priced in a worst-case scenario, implying Nevro will lose all IP protection over its HF-10kHz technology, but he believes the current situation is more nuanced and the ultimate outcomes remain fluid. He believes the market overreacted and he recommends investors buy the weakness. Mills reiterated his Buy rating and $80 price target on Nevro shares.
NBIX Neurocrine
$110.55

-5.28 (-4.56%)

10/05/18
PIPR
10/05/18
NO CHANGE
Target $115
PIPR
Overweight
Piper positive on Neurocrine potential in Tourette's after doctor survey
After conducting a survey of 25 psychiatrists who manage pediatric patients with Tourette syndrome, Piper Jaffray analyst David Amsellem has heightened confidence that Neurocrine Biosciences' Ingrezza will have a significant role in the treatment landscape. To the extent that there is a label expansion in Tourette's, the product is likely to be seen as a more attractive dopaminergic-based agent relative to atypical antipsychotics, Amsellem tells investors in a research note. The analyst continues to believe that the upside potential for Neurocrine shares associated with favorable results in Tourette's is "significantly larger than the downside risk associated with a clinical setback." He reiterates an Overweight rating on the shares with a $115 price target.
09/20/18
STFL
09/20/18
NO CHANGE
Target $142
STFL
Buy
Neurocrine odds of success in Tourette's raised to 75% at Stifel
Stifel analyst Paul Matteis said his additional research on approved Tourette's Syndrome therapies, treatment guidelines, and the details of the T-FORCE GOLD study make him bullish that Neurocrine's valbenazine should succeed in its "very well powered" Phase 3 trial. The analyst, who believes the stock currently prices in a 40%-50% probability of success, raised his own take on the odds of success for the valbenazine program to 75% from 60%. He keeps a Buy rating on Neurocrine shares and increased his price target on the stock to $142 from $137.
09/19/18
CANT
09/19/18
NO CHANGE
Target $150
CANT
Overweight
Cantor more confident in Neurocrine after speaking with physician
After hosting a call with a physician who has "deep expertise" in movement disorders and is familiar with the use of VMAT2 inhibitors in various hyperkinetic disorders, having treated thousands of pediatric Tourette's Syndrome patients, Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on Neurocrine Biosciences with a $150 price target. The physician noted that current approved treatments in Tourette's Syndrome, haloperidol, pimozide, and aripiprazole come with "many unwanted side effects that clearly overshadow any efficacy benefits," Duncan tells investors in a research note. The doctor he spoke to almost never uses these drugs in his pediatric Tourette's Syndrome patients, instead preferring off-label medications. Duncan says he now has increased conviction in not only the probability of Neurocrine's TForce Gold trial success, but also in the market opportunity for valbenazine in Tourette's Syndrome. He reiterates an Overweight rating on the shares with a $150 price target.
09/14/18
CANT
09/14/18
NO CHANGE
Target $150
CANT
Overweight
Cantor sees favorable Tourette's readout for Neurocrine by end of year
Cantor Fitzgerald analyst Charles Duncan believes the T-Force Gold study benefits from the past experience Neurocrine Biosciences has in Tourette's syndrome. The study will read out as "interpretable, and favorable" by the end of 2018 to support a supplemental new drug application possibly in the first half of 2019, Duncan tells investors in a research note. The analyst keeps an Overweight rating on Neurocrine with a $150 price target.
PTCT PTC Therapeutics
$38.02

-1.59 (-4.01%)

10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/03/18
BOFA
10/03/18
UPGRADE
BOFA
Neutral
PTC Therapeutics upgraded to Neutral from Underperform at BofA/Merrill
10/03/18
PIPR
10/03/18
NO CHANGE
PIPR
Overweight
PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray
The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.
10/03/18
JPMS
10/03/18
NO CHANGE
JPMS
PTC Therapeutics 'unfounded' weakness a buying opportunity, says JPMorgan
BE Bloom Energy
$23.08

0.22 (0.96%)

10/31/18
10/31/18
UPGRADE
Target $24

Neutral
Bloom Energy upgraded to Neutral ahead of quarterly results at Credit Suisse
As previously reported, Credit Suisse analyst Michael Weinstein upgraded Bloom Energy to Neutral from Underperform, with a $24 price target. The analyst cited recent sharp underperformance, as he expects in-line system/price guidance for the company's debut earnings call.
10/31/18
FBCO
10/31/18
UPGRADE
FBCO
Neutral
Bloom Energy upgraded to Neutral from Underperform at Credit Suisse
10/17/18
JPMS
10/17/18
NO CHANGE
JPMS
JPMorgan constructive on some Alternative Energy names into Q3 results
JPMorgan analyst Paul Coster says he's constructive regarding a handful of Alternative Energy stocks heading into the Q3 earnings season. The analyst sees more attractive valuations after the recent selloff and names his top picks as First Solar (FSLR), TPI Composites (TPIC), Hannon Armstrong (HASI) and Bloom Energy (BE). First Solar remains "best-in-class" in the solar space, has good revenue and earnings visibility, and seems best-positioned to ride out the second half of 2018 panel downturn, Coster tells investors in a research note.
08/27/18
08/27/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. MORGAN STANLEY DOUBLE DOWNGRADES U.S. STEEL: Morgan Stanley analyst Piyush Sood double downgraded U.S. Steel (X) to Underweight from Overweight as he notes that steel prices are falling and he believes the recent price peak is "firmly behind" the market. Sood lowered his price target on U.S. Steel shares to $30 from $44. He prefers AK Steel (AKS), which he upgraded to Overweight from Equal Weight citing its good free cash flow prospects, and also prefers Steel Dynamics (STLD), which he also upgraded to Overweight from Equal Weight. PAPA JOHN'S UPGRADED TO BUY: Kalinowski Equity Research's Mark Kalinowski upgraded Papa John's (PZZA) to Buy from Neutral as he believes the reported hiring of Bank of America and Lazard increases the odds of a favorable outcome over the next 12 months, including the possibility of an acquisition. He noted that CNBC reports the company "isn't currently exploring a sale," but he believes a sale makes a lot of sense. BLOOM ENERGY CUT TO UNDERPERFORM: Credit Suisse analyst Michael Weinstein downgraded Bloom Energy (BE) to Underperform from Neutral, with a $24 price target on the stock, on valuation. While the analyst acknowledged the disruptive potential of Bloom Energy's technology, the stock is now trading at a premium. Although the company has shown impressive success so far, much work remains to be done to continue lowering costs and deliver next generation improvements, he contended. WEDBUSH CUTS CHIPOTLE TO UNDERPERFORM: Wedbush analyst Nick Setyan downgraded Chipotle Mexican Grill (CMG) to Underperform from Neutral and lowered his price target for the shares to $445 from $450. Setyan sees increased risk to Chipotle's near-term same-store-sales growth and margin expectations, and continues to see risk to margin expectations through 2020. Quarter-to-date checks suggest risk to the current Q3 consensus same-store-sales growth expectation, Setyan said. Further, the analyst believes that while theoretical drivers towards 2019 same-store-sales growth expectations exist, the risks are underappreciated.
MAR Marriott
$120.74

-0.14 (-0.12%)

10/22/18
COWN
10/22/18
INITIATION
COWN
Outperform
Marriott initiated with an Outperform at Cowen
Cowen analyst Kevin Kopelman initiated Marriott with an Outperform rating and $140 price target, and added it to his Top Picks, noting the scale advantages of Marriott's $76B system revenue, the company's large pipeline across tiers and geographies, and its accrued loyalty.
09/07/18
LBOW
09/07/18
INITIATION
Target $156
LBOW
Buy
Marriott initiated with a Buy at Longbow
Longbow analyst Alton Stump initiated Marriott with a Buy and $156 price target given accelerating RevPAR growth, potential accelerating net room count growth, and a favorable economic landscape.
08/28/18
RHCO
08/28/18
INITIATION
Target $14
RHCO
Buy
Playa Hotels & Resorts initiated with a Buy at SunTrust
SunTrust analyst C. Patrick Scholes initiated Playa Hotels & Resorts with a Buy rating and a price target of $14, saying the company's growth strategy through and beyond 20201 is "highly compelling". The analyst sees annualized adjusted EBITDA growth through 2021 at 15% or more, which is the highest growth rate in the period across his hotel coverage group. Scholes adds that leisure demand has been strong, with an increase in consumer interest toward the "high-quality all-inclusive resorts" and notes that Playa Hotels may become the "first adopter of an all-inclusive brand from Hilton (HLT) and/or Marriott (MAR)" in the near future.
08/17/18
BERN
08/17/18
DOWNGRADE
BERN
Market Perform
Hilton downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst David Beckel downgraded Hilton (HLT) to Market Perform from Outperform, telling investors that Hilton's current valuation fairly reflects his expectation of an environment in which U.S. RevPAR and unit growth decelerate over the next 12 months, potentially faster than currently forecast. He expects a combination of slowing growth and a lack of catalysts will limit upside for both Hilton and Market Perform-rated Marriott (MAR) during that time.
CAR Avis Budget
$31.10

0.965 (3.20%)

10/16/18
10/16/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. NEEDHAM SAYS BUY TAPESTRY: Needham analyst Rick Patel upgraded Tapestry to Buy from Hold and kept his $50 price target. The analyst notes that after a 14% selloff in the stock price driven by tariff-related concerns and the slowdown of Asia sales at LVMH, the risk-reward is favorable. Patel estimates that the hit to EPS from the impact of the handbag tariff should be "relatively modest" at about 1%. The analyst further notes that Tapestry has "ample white space" for long term growth in China through new distribution, while its North America sales indicate "well-controlled promotions" for Coach and Kate Spade. ANALYSTS SAY BUY FACEBOOK IN NEW INITIATIONS: Loop Capital analyst Alan Gould initiated Facebook with a Buy rating and a price target of $210, saying the stock is valued "quite attractively" after a "strong year financially and a challenging year operationally". The analyst also notes that the company's guidance is likely "conservative" given the company's propensity to beat consensus estimates. Meanwhile, Rosenblatt analyst Mark Zgutowicz started Facebook with a Buy rating in a note partially entitled "Facebook: Value, Not Trap." Given the stock's current valuation, there appears to be little confidence consensus expectations will be met and he is "in that camp," forecasting calendar 2019 EPS that is about 8% below consensus, Zgutowicz tells investors. However, with that said, he sees the anticipated EPS shortfall as priced in the shares and would be a buyer of the stock in front of the Q3 report, stating that he sees a bottoming for News Feed fatigue and enough light ahead with new product innovation and Instagram and Watch optionality. Zgutowicz set a $213 price target on Facebook shares. TILRAY TARGET SET AT $200 AS CANADA GETS READY TO LEGALIZE: Benchmark analyst Mike Hickey initiated coverage of Tilray with a Buy rating and $200 price target, citing its early leadership in the medical cannabis market in Canada and the upcoming legalization of recreational cannabis, which begins in the North American nation tomorrow. He believes the company's strategic alliance with Novartis (NVS) and supply agreements with Canadian pharmacies that give Tilray a competitive edge in the Canadian medical cannabis market, Hickey tells investors. He also believes the potential international opportunity is "enormous," estimating that the global cannabis market opportunity could exceed $200B over the long-term. JEFFERIES SEES NO COMPETING BIDS FOR PINNACLE: Jefferies analyst Akshay Jagdale downgraded Pinnacle Foods (PF) to Hold from Buy and lowered his price target for the shares to $68 from $72. The analyst assumes Conagra Brands' (CAG) bid to buy the company for $68 will go through without any competing bids. The stock should trade in line with its $68 transaction price until completion of the deal, Jagdale tells investors. GOLDMAN PREDICTS AVIS, HERTZ OUTLOOKS WILL DISAPPOINT: Goldman Sachs analyst David Tamberrino nudged the price target on Avis Budget (CAR) lower to $30 from $31 while keeping the price target on Hertz at $13 as part of his broader research note previewing Q3 results for the two Sell-rated U.S. car rental names. The analyst notes that Hertz (HTZ) may top Q3 consensus earnings and Avis Budget could miss based on his analysis of their respective pricing trends and residual values, but both have an added risk from reduced airport volume growth amid tightening competition among the ride hailing operators like Uber and Lyft. Tamberrino expects the car rental industry to remain challenged overall, noting that positive pricing will not be sustained, residual values will be pressured as more cars come off lease, and rising interest rates exert pressure on their balance sheets' high debt levels.
10/16/18
GSCO
10/16/18
NO CHANGE
Target $30
GSCO
Sell
Goldman Sachs expects FY18 outlook for Avis Budget and Hertz to disappoint
Goldman Sachs analyst David Tamberrino nudged the price target on Avis Budget (CAR) lower to $30 from $31 while keeping the price target on Hertz at $13 as part of his broader research note previewing Q3 results for the two Sell-rated U.S. Car Rental names. The analyst notes that Hertz (HTZ) may top Q3 consensus earnings and Avis Budget could miss based on his analysis of their respective pricing trends and residual values, but both have an added risk from reduced airport volume growth amid tightening competition among the ride hailing operators like Uber and Lyft. Tamberrino expects the car rental industry to remain challenged overall, noting that positive pricing will not be sustained, residual values will be pressured as more cars come off lease, and rising interest rates exert pressure on their balance sheets' high debt levels.
07/30/18
07/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Buy from Neutral at BofA/Merrill with analyst David Barden saying he is positive on AT&T's 20-year low P/E multiple, Timer Warner (TWX) merger benefits of earnings accretion and expanding cash, favorable emerging wireless business trends, and a call option on value extraction from the merger of AT&T's distribution network with Time Warner's content and ad inventory. 2. American Airlines (AAL) upgraded to Outperform from Neutral at Macquarie. 3. Avis Budget (CAR) upgraded to Buy from Neutral at Northcoast. 4. Cabot Oil & Gas (COG) upgraded to Positive from Neutral at Susquehanna with analyst Biju Perincheril citing the recent weakness in the shares but he also feels the risk/reward is attractive with many projects providing production growth over the next two years along with accelerating free cash flow generation. 5. Juniper (JNPR) upgraded to Buy from Hold at Deutsche Bank with analyst Vijay Bhagavath saying he's "going against the grain" and making a "contrarian call." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/18
NRCS
07/30/18
UPGRADE
NRCS
Buy
Avis Budget upgraded to Buy from Neutral at Northcoast
THC Tenet
$27.20

0.05 (0.18%)

08/14/18
LEHM
08/14/18
INITIATION
LEHM
Barclays starts Hospital sector with Neutral outlook, top pick HCA
Barclays analyst Steve Valiquette initiated coverage of the Hospital sector with a Neutral rating. Operators continue to face incremental pressures from alternative payment models that are shifting incentives towards lower-cost sites of care, Valiquette tells investors in a research note. He believes, however, that despite industry headwinds, operators levered to markets with high population growth and high relative market share will continue to outperform the industry. The analyst's only Overweight rated name in space is HCA Healthcare (HCA). The analyst initiated coverage of HCA with an Overweight rating and $150 price target. He sees HCA as well positioned in local markets. Valiquette also started Universal Health Services (UHS) and Tenet Healthcare (THC) with Equal Weight ratings. His lone Underweight rating is put on Community Health Systems (CYH). The company is still burdened with excessive debt and constrained free cash flow from its rural hospital footprint, Valiquette contends.
08/14/18
LEHM
08/14/18
INITIATION
Target $35
LEHM
Equal Weight
Tenet initiated with an Equal Weight at Barclays
Barclays analyst Steven Valiquette started Tenet Healthcare with an Equal Weight rating and $35 price target.
08/08/18
MZHO
08/08/18
NO CHANGE
Target $36
MZHO
Buy
Tenet post-earnings selloff seems overdone, says Mizuho
Mizuho analyst Ann Hynes believes the post-earnings selloff yesterday in shares of Tenet Healthcare seems overdone. The Q2 earnings report shows Tenet has initiatives underway that should improve its earnings, margin and cash flow profile, Hynes tells investors in a research note. The analyst raised her price target for the shares to $36 from $35 and keeps a Buy rating on Tenet.
07/23/18
SBSH
07/23/18
NO CHANGE
Target $44
SBSH
Buy
Tenet price target raised to $44 from $37 at Citi
Citi analyst Ralph Giacobbe raised his price target for Tenet Healthcare to $44 saying he sees additional upside in the stock despite the 140% rally year-to-date. There is an underappreciation for additional upside within the hospital segment specifically around margin improvement, Giacobbe tells investors in a research note partially titled "Debunking the Rationale for Lower Margins." He keeps a Buy rating on Tenet.
REN Resolute Energy
$30.97

0.66 (2.18%)

06/14/18
IMPC
06/14/18
NO CHANGE
IMPC
Outperform
Imperial Capital sees attractive valuations for Permian names
The market has overreacted to the "inevitable traffic jams and competition for outbound transportation" taking place in the Permian region, Imperial Capital analysts Irene Haas and Jason Wangler tells investors in a research note. Following conversations with industry participants in both the upstream and midstream arenas of the Permian Region, the analysts believes relief for oil could materialize in early 2019. They sees a "handful of high quality Permian names at attractive valuations," including Diamondback Energy (FANG), Resolute Energy (REN), Ring Energy (REI), Callon Petroleum (CPE), Matador Resources and PDC Energy (PDCE).
04/16/18
RHCO
04/16/18
DOWNGRADE
Target $41
RHCO
Hold
Resolute Energy downgraded to Hold from Buy at SunTrust
SunTrust analyst Neal Dingmann downgraded Resolute Energy to Hold from Buy and lowered his price target to $41 from $44 as part of his broader research note on Q1 reporting season for companies in the Permian basin. Dingmann says that while he expects the company to post strong production growth this year, its plan to "tackle batch completions" could prove challenging, leading output to be weighted toward the back end of 2018 and potentially more lumpy. The analyst also points to Resolute Energy's valuation, with the stock price having risen about 12% year-to-date relative to a 2% decline average among its Permian peers.
04/16/18
RHCO
04/16/18
DOWNGRADE
RHCO
Hold
Resolute Energy downgraded to Hold from Buy at SunTrust
04/12/18
GSCO
04/12/18
DOWNGRADE
Target $39
GSCO
Neutral
Resolute Energy downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst John Nelson downgraded Resolute Energy to Neutral from Buy, saying that he now sees its operational execution as being discounted in shares following outperformance versus SMID Permian E&Ps. However, he does think that shareholder activism, which he believes has contributed to Resolute's recent outperformance, could continue to be a near-term driver of share price, Nelson tells investors. He lowered his price target on Resolute shares to $39 from $52.
OAS Oasis Petroleum
$10.23

0.37 (3.75%)

10/29/18
IFSG
10/29/18
INITIATION
Target $14
IFSG
Outperform
Oasis Petroleum initiated with an Outperform at IFS Securities
IFS Securities analyst Eli Kantor initiated Oasis Petroleum with an Outperform rating and $14 price target, noting that the Williston Basin one of the few areas in the U.S. onshore where well performance continues to improve. He expects this to result in future production beats and share price outperformance for Oasis, Kantor tells investors.
10/17/18
WOLF
10/17/18
UPGRADE
WOLF
Outperform
Oasis Petroleum upgraded to Outperform from Peer Perform at Wolfe Research
10/15/18
JEFF
10/15/18
UPGRADE
Target $15
JEFF
Buy
Oasis Petroleum upgraded to Buy from Hold at Jefferies
Jefferies analyst Mark Lear upgraded Oasis Petroleum to Buy and raised his price target for the shares to $15 from $13. The analyst attributes the pullback in the shares to the general market selloff and concerns over Bakken differentials. He cites valuation for the upgrade as he sees an attractive valuation at current share levels.
10/02/18
OPCO
10/02/18
INITIATION
OPCO
Perform
Oasis Petroleum initiated with a Perform at Oppenheimer
Oppenheimer analyst Tim Rezvan initiated Oasis Petroleum with an Perform rating.
LPI Laredo Petroleum
$5.44

0.15 (2.84%)

05/10/18
TUDR
05/10/18
DOWNGRADE
TUDR
Hold
Laredo Petroleum downgraded to Hold from Buy at Tudor Pickering
05/03/18
BARD
05/03/18
DOWNGRADE
BARD
Neutral
Laredo Petroleum downgraded to Neutral from Outperform at Baird
03/28/18
ROTH
03/28/18
NO CHANGE
Target $50.5
ROTH
Buy
Concho acquisition of RSP may be catalyst for Permian consolidation, says Roth Capital
Roth Capital analyst John White notes that Concho Resources (CXO) and RSP Permian announced they have entered into a definitive agreement under which the former will acquire the latter in an all-stock transaction valued at approximately $9.5B, inclusive of RSP's net debt. The analyst believes this transaction could potentially be a catalyst for additional consolidation in the Permian Basin. White points out that there are a large number of small and mid-cap operators active in the basin, including Approach Resources (AREX), Callon Petroleum (CPE), Diamondback Energy (FANG), Earthstone Energy (ESTE), Halcon Resources (HK), Laredo Petroleum (LPI), Matador (MTDR), Parsley Energy (PE), Ring Energy (REI). The analyst has a Buy rating and $50.50 price target on RSP Permian's shares.
02/01/18
DBAB
02/01/18
INITIATION
Target $11
DBAB
Hold
Laredo Petroleum initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Nitin Kumar started Laredo Petroleum with a Hold rating and $11 price target.
TISI Team
$19.53

-0.37 (-1.86%)

01/23/18
JRCO
01/23/18
UPGRADE
Target $24
JRCO
Accumulate
Team upgraded to Accumulate from Hold at Johnson Rice
Johnson Rice upgraded Team to Accumulate and raised its price target to $24 from $18 saying the company entered 2018 with an improved cost structure and more favorable end markets. The firm notes Team appointed a new CEO last week and recently completed the roll-out of its ERP system to its U.S. facilities and is taking steps to adjust its cost structure.
01/22/18
SPHN
01/22/18
UPGRADE
Target $22
SPHN
Overweight
Team upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Matt Duncan upgraded Team to Overweight from Equal Weight, stating that he expects the company to get the covenant waiver it will need from its bank group by the end of March. Also, the downstream energy market is showing signs of recovery in 2018 and phase 2 of Team's cost cutting plan should be announced by likely early March, added Duncan, who raised his price target on Team shares to $22 from $16.
11/08/17
JRCO
11/08/17
UPGRADE
Target $18
JRCO
Accumulate
Team upgraded to Accumulate from Hold at Johnson Rice
Johnson Rice analyst Martin Malloy upgraded Team to Accumulate and maintained an $18 price target citing valuation, and improved cost structure, a new CEO, and more favorable end markets.
AKCA Akcea Therapeutics
$27.03

1.73 (6.84%)

10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
10/08/18
CANT
10/08/18
INITIATION
Target $135
CANT
Overweight
Cantor reiterates Overweight on Alnylam after Akcea, Ionis win approval
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $135 price target after the FDA approved Tegsedi, to be marketed by Akcea Therapeutics (AKCA). The analyst says that while the approval introduces another competitor to the market, she still expects Alnylam's Onpattroto be able to take significant share in the polyneuropathy hATTR market. Young thinks the Tegsedi label is more onerous and currently models a 60% peak share to Alnylam, a 25% share to Tegsedi and 15% to future competition.
10/07/18
PIPR
10/07/18
NO CHANGE
Target $160
PIPR
Overweight
Alnylam's Onpattro highly efficacious, safer than competitor, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Ionis Pharmaceuticals (IONS) announced FDA approval of TEGSEDI for treatment of hATTR polyneuropathy. The analyst also points out that the label includes a Black Box warning for thrombocytopenia and glomerulonephritis requiring every 2-week monitoring, and will be marketed by Ionis subsidiary Akcea (AKCA) with a Risk Evaluation and Mitigation Strategy. TEGSEDI is administered subcutaneously every week versus Alnylam's (ANLY) ONPATTRO intravenously every 3 weeks with steroids, he adds. Tenthoff believes that ONPATTRO appears safer and highly efficacious, and should win out. The analyst reiterates an Overweight rating and $160 price target on Alnylam shares.
09/18/18
NEED
09/18/18
INITIATION
Target $45
NEED
Buy
Akcea Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Akcea Therapeutics (AKCA) with a Buy rating and a price target of $45, saying it is an "attractive" way for investors to leverage "decades of innovation" by the parent Ionis Pharma (IONS) through ownership of its most advanced-stage programs. The analyst cites the unfolding "breakthrough" in the approval of a new class of antisense drugs which "directly block protein synthesis in cells by binding to RNA". Messer adds that Akcea is positioned for near-term commercial opportunity for its Tegsedi and Waylivra programs.
ANDE Andersons
$37.00

0.37 (1.01%)

08/08/18
08/08/18
UPGRADE
Target $44

Overweight
Stephens upgrades Andersons to Overweight on better wheat, fertilizer conditions
As previously reported, Stephens analyst Farha Aslam upgraded Andersons to Overweight from Equal Weight, citing her view that the company is well positioned to benefit from tight global supplies of wheat given global trade disruptions. She also contends that fertilizer earnings should benefit from rising prices. Aslam raised her price target on Andersons shares to $44 from $40.
08/08/18
SPHN
08/08/18
UPGRADE
SPHN
Overweight
Andersons upgraded to Overweight from Equal Weight at Stephens
02/16/18
BMOC
02/16/18
NO CHANGE
Target $38
BMOC
Market Perform
Andersons price target raised to $38 from $34 at BMO Capital
BMO Capital analyst Kenneth Zaslow raised his price target on Andersons after a Q4 earnings beat that reflected a rebound in grain and ethanol performance. The outlook for FY18 is also positive on improving grain business from recovery in Lansing and better ethanol, though accounting changes and higher tank car expenses are set to pressure rail, the analyst contends. Zaslow keeps his Market Perform rating on Andersons while the company undergoes an "operational evolution".
11/08/17
11/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) was downgraded to Underweight from Neutral at JPMorgan, to Sector Perform from Outperform at RBC Capital, and to Hold from Buy at Stifel. 2. Mallinckrodt (MNK) was downgraded to Neutral from Buy at Goldman Sachs, to Equal Weight from Overweight at Barclays, and to Market Perform from Outperform at Wells Fargo. 3. Scotts Miracle-Gro (SMG) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas saying he finds the shares fairly valued at current levels. 4. Andersons (ANDE) downgraded to Neutral from Buy at Buckingham with analyst Eric Larson citing the weaker than expected third quarter report and guidance. 5. Townsquare Media (TSQ) downgraded to Equal Weight from Overweight at Stephens with analyst Kyle Evans saying the Local Marketing Services business appears healthy but he is unwilling to wait another year for signs of improvement in its struggling Entertainment business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ACHC Acadia
$40.49

-4.27 (-9.54%)

10/18/18
FBCO
10/18/18
NO CHANGE
FBCO
Acadia could be worth $43 per share in takeout, says Credit Suisse
In his leveraged buyout scenario, Credit Suisse analyst A.J. Rice says Acadia could be worth $43 per share. The analyst assumes top-line growth in the 6%-7% range and that margins grow from 21% in 2018 to 22.7% by 2023. Further, Rice believes the buyer could split the U.S. and U.K. businesses, which would likely be immediately accretive to the valuation of the U.S. business and give optionality to bringing on a partner on the U.K. side. The analyst notes that leveraged buyouts are not new to Acadia management, but adds that he sees no obvious strategic buyer here.
10/18/18
BARD
10/18/18
NO CHANGE
Target $42
BARD
Neutral
Baird puts Acadia buyout price at $40-$45, says not chasing shares
Baird analyst Matthew Gillmor is not surprised by the reports that Acadia Healthcare is in talks to sell itself to private equity firms given considering management's history and the complexities with the U.K. business. His analysis suggests a leveraged buyout in the $40 to $45 per share range "could make sense" for a private equity bidder, with "perhaps some optionality" from separating the U.S. and U.K. operations over time. With the stock trading "just" 10% below his leveraged buyout takeout valuation, Gillmor says he's not inclined to chase the stock on today's rally. He keeps a Neutral rating on Acadia with a $42 price target. The stock in morning trading is up 9%, or $3.23, to $39.00.
10/18/18
LEER
10/18/18
NO CHANGE
LEER
Acadia may receive 11-12 times multiple in private equity takeout, says Leerink
Following reports saying KKR (KKR) and TPG Global are reportedly in talks with Acadia (ACHC) on a take-private deal, Leerink analyst Ana Gupte notes that private equity has always been interested in the company given its addiction treatment centers acquired through CRC Health and outpatient focus on eating disorders and substance abuse, though the multiples at which a takeout would be acceptable to Acadia's management were unclear. The analyst expects the recent news flow on understaffing and quality of service delivery at Acadia in the short news report may be driving more willingness to entertain such a take private of the company. Gupte believes a 11-12 times multiple is likely and represents upside of about 35%-55% on the current $35 per share trading price.
10/18/18
MZHO
10/18/18
NO CHANGE
Target $37
MZHO
Neutral
Mizuho sees maximum Acadia leveraged buyout price at $48 per share
Mizuho analyst Ann Hynes reiterates this morning that her model suggests Acadia Healthcare's (ACHC) maximum leveraged buyout take-out price is $48.00 per share given its current debt levels. The stock in premarket trading is up 8%, or $3.32, to $39.00 after Reuters reported that the company is in talks with private equity firms about selling itself after attracting buyout interest. KKR (KKR) and TPG Global are among the private equity firms that have approached Acadia, according to Reuters. Hynes keeps a Neutral rating on Acadia shares with a $37 price target.
VVV Valvoline
$20.78

0.395 (1.94%)

10/03/18
JEFF
10/03/18
INITIATION
Target $27
JEFF
Buy
Valvoline initiated with a Buy at Jefferies
Jefferies analyst Laurence Alexander started Valvoline with a Buy rating and $27 price target. The company has successfully navigated a rising raw material environment, allaying a key investor concern after the spin off, Alexander tells investors in a research note.
09/17/18
GHSC
09/17/18
UPGRADE
GHSC
Buy
Valvoline upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Michael Harrison upgraded Valvoline to Buy and maintained a $25 price target. Harrison believes last week's selloff is "overblown" and an excellent buying opportunity to involved the the growth stry driven by Quick Lubes and International. The analyst expects normalizing trends in the Core North American segment in Q4, noting base oil prices appear to be stabilizing, and further announcements that the company is adding stores to its quick-lube network.
09/14/18
09/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Costco (COST) downgraded to Market Perform from Outperform at Wells Fargo with analyst Edward Kelly saying while Costco remains one of the highest quality companies within consumer and its near-term results should be positive, "this may be as good as it gets." 2. Dunkin' Brands (DNKN) downgraded to Sector Perform from Outperform at RBC Capital with analyst David Palmer saying while sales have accelerated sequentially, the current valuation of 22-times his expected FY20 earnings "reflects much of the turnaround." 3. Valvoline (VVV) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying industry trade publication National Oil and Lube New is reporting that Amazon (AMZN) has launched its first private label motor oil called AmazonBasics Full Synthetic Motor Oil. 4. DDR Corp. (DDR) downgraded to Neutral from Buy at Citi. 5. Tandem Diabetes (TNDM) downgraded to Neutral from Outperform at Baird with analyst Jeff Johnson saying at some point valuation will matter, so he moved to the sidelines. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/18
09/14/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. WELLS SAYS 'MAY BE AS GOOD AS IT GETS' FOR COSTCO: Wells Fargo analyst Edward Kelly downgraded Costco Wholesale to Market Perform from Outperform with an unchanged price target of $235. While Costco remains one of the highest quality companies within consumer and its near-term results should be positive, "this may be as good as it gets," Kelly told investors. He believes the stock's 50% rally over the past year "has left it priced for perfection" and that Costco's comps "seem destined to slow in 2019" as it laps tough comparisons. JPMORGAN ADVISE CAUTION ON GE: A read of the proxies for the General Electric (GE) and Wabtec (WAB) transportation deal suggests "caution is warranted" in taking the forecasts "to the bank," JPMorgan analyst Stephen Tusa wrote in a research note. The situation "looks eerily similar" to GE's Baker Hughes (BHGE) deal, where management went from pitching $8B in future EBITDA several years forward to "slowly pulling annual guidance once public," with a consensus that is now at $5B, Tusa said. He believes that as each of GE's Industrial businesses get broken out clearly with "clean GAAP" transparency, the less impressive the financials look. Tusa keeps an Underweight rating on General Electric shares. CORNING UPGRADED ON OPTICAL DEMAND STRENGTH: Citi analyst Asiya Merchant upgraded Corning (GLW) to Buy from Neutral with a $40 price target, telling investors that the shares are "poised to continue to grind higher" in the next 12-18 months. The analyst expects Corning's earnings and margins growth will be driving by optical demand strength and better display pricing. JPMORGAN CUTS VALVOLINE TO UNDERWEIGHT ON NEW AMAZON COMPETITION: JPMorgan analyst Jeffrey Zekauskas downgraded Valvoline (VVV) to Underweight from Neutral and lowered his price target for the shares to $20 from $22. Industry trade publication National Oil and Lube New is reporting that Amazon (AMZN) has launched its first private label motor oil called AmazonBasics Full Synthetic Motor Oil, Zekauskas noted. While too early to gauge the effects of the Amazon entry on the Valvoline brand, the new competition from Amazon will likely reduce Valvoline's trading multiple "because the lubricant industry structure is probably weaker for its entry," Zekauskas contends. NVIDIA TARGET HIKED TO $350: Needham analyst Rajvindra Gill raised his price target on Nvidia to $350 from $325 after his investor meeting with its Data Center GM and Director of IR, saying the discussions about the company's AI/ML dominance reminded him of "Wintel" platform during the PC computing era. The analyst believes that Nvidia is "uniquely positioned" to capitalize on the next wave of computing, taking a larger inference market share with its new TensorRT Hyperscaler Platform.
LMNX Luminex
$29.61

-0.32 (-1.07%)

09/27/18
PIPR
09/27/18
NO CHANGE
PIPR
Neutral
Piper says about $3.5M of Luminex revenue at risk from Medicare determination
After Palmetto's MolDx released a final local coverage determination that panels of 3-5 pathogens will be covered, but larger panels will not be, Piper Jaffray analyst William Quirk said he believes 51% of the population is covered by MACs that follow MolDX. In terms of the decision's implications for Luminex, Quirk said he sees $3M-$4M in exposure to MolDx Medicare for Luminex's xTAG and Nanosphere tests. He also noted that Luminex management has talked about unbundling to make their panels smaller, which he believes will be the likely outcome. Quirk has a Neutral rating on Luminex shares.
05/07/18
DBAB
05/07/18
UPGRADE
Target $22
DBAB
Hold
Luminex upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Dan Leonard upgraded Luminex to Hold and raised his price target for the shares to $22 from $19. The analyst views the risk/reward as balanced at current share levels.

TODAY'S FREE FLY STORIES

PAR

Par Technology

$30.23

1.07 (3.67%)

18:08
11/11/19
11/11
18:08
11/11/19
18:08
Recommendations
Par Technology analyst commentary  »

Par Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:06
11/11/19
11/11
18:06
11/11/19
18:06
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Yageo to acquire Kemet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CSX

CSX

$73.93

-0.08 (-0.11%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Downgrade
CSX rating change  »

CSX downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TDW

Tidewater

$17.14

-0.34 (-1.95%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Earnings
Tidewater reports Q3 adjusted EPS (99c), may not compare to consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UNVR

Univar

$23.87

-0.08 (-0.33%)

17:57
11/11/19
11/11
17:57
11/11/19
17:57
Hot Stocks
Univar named EMEA distributor for Kaopolite Abrasive in Europe »

Univar B.V., a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXRT

NexPoint Residential

$46.48

0.44 (0.96%)

17:56
11/11/19
11/11
17:56
11/11/19
17:56
Hot Stocks
NexPoint Residential acquires three-property portfolio in Las Vegas for $241M »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Breaking Hot Stocks news story on DXC Technology »

DXC reverses course, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Fluent drops over 22% after reporting Q3 results, lowers FY19 revenue view »

Shares of Fluent are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Hot Stocks
DXC Technology to pursue strategic alternatives for three businesses »

Says as part of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Earnings
Fluent lowers FY19 revenue view to $87M-$88M from $93M-$98M »

Sees adjusted EBITDA is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

HBM

Hudbay Minerals

$3.66

-0.09 (-2.40%)

17:36
11/11/19
11/11
17:36
11/11/19
17:36
Earnings
Hudbay Minerals reports Q3 EPS ($1.05), consensus 18cc »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:34
11/11/19
11/11
17:34
11/11/19
17:34
Earnings
Fluent reports Q3 EPS (1c), consensus 2c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

MDGL

Madrigal Pharmaceuticals

$103.57

0.78 (0.76%)

17:34
11/11/19
11/11
17:34
11/11/19
17:34
Hot Stocks
Madrigal announces publication of 'positive' Phase 2 results for resmetirom »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KINS

Kingstone Companies

$8.72

-0.04 (-0.46%)

17:32
11/11/19
11/11
17:32
11/11/19
17:32
Earnings
Kingstone Companies reports Q3 EPS (23c), two estimates 28c »

Reports Q3 net written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

17:32
11/11/19
11/11
17:32
11/11/19
17:32
Earnings
Kemet sees Q3 revenue down 8%-13% sequentially, consensus $323.97M »

CEO, William Lowe Jr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

17:31
11/11/19
11/11
17:31
11/11/19
17:31
Earnings
Kemet reports Q2 adjusted EPS 66c, consensus 66c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NTZ

Natuzzi

$1.70

0.1 (6.25%)

17:21
11/11/19
11/11
17:21
11/11/19
17:21
Hot Stocks
Natuzzi Chief Commercial Officer Nazzario Pozzi departs »

Natuzzi announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

17:18
11/11/19
11/11
17:18
11/11/19
17:18
Earnings
Breaking Earnings news story on UGI Corporation »

UGI Corporation sees FY20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

17:17
11/11/19
11/11
17:17
11/11/19
17:17
Earnings
UGI Corporation reports Q4 EPS (27c), consensus (4c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

, GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

17:05
11/11/19
11/11
17:05
11/11/19
17:05
Periodicals
State AGs gather in Colorado to go over Google antitrust probe, Reuters says »

State attorneys general…

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

FB

Facebook

$189.57

-1.29 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:03
11/11/19
11/11
17:03
11/11/19
17:03
Hot Stocks
Franco-Nevada reports 133,219 Gold Equivalent Ounces sold in Q3 »

"Franco-Nevada's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:02
11/11/19
11/11
17:02
11/11/19
17:02
Earnings
Franco-Nevada reports Q3 EPS 54c, may not compare to consensus 27c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ENR

Energizer

$43.11

-0.265 (-0.61%)

16:55
11/11/19
11/11
16:55
11/11/19
16:55
Hot Stocks
Energizer appoints new CFO, Chief Legal Officer, and Chief Accounting Officer »

Energizer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 21

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

16:52
11/11/19
11/11
16:52
11/11/19
16:52
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.